Nonadenomatous dysplasia in barrett esophagus: A clinical, pathologic, and DNA content flow cytometric study

American Journal of Surgical Pathology

Volumn 33, Issue 6, 2009, Pages 886-893

  Rucker Schmidt, Rachel L ^a   Sanchez, Carissa A ^b   Blount, Patricia L ^b,c   Ayub, Kumran ^e,f,g   Li, Xiahong ^b   Rabinovitch, Peter S ^c   Reid, Brian J ^b,c,d   Odze, Robert D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b USA   (United States)

^c Department of Medicine ^*

^d UNIVERSITY OF WASHINGTON   (United States)

^e Department of Provena   (United States)

^f Department of Adventist   (United States)

^g ADVOCATE CHRIST MEDICAL CENTER   (United States)

Author keywords

Aneuploidy; Barrett esophagus; Dysplasia; Esophageal adenocarcinoma; Tetraploidy

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA CONTENT; DYSPLASIA; ENDOSCOPY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METAPLASIA; NONADENOMATOUS DYSPLASIA; PROSPECTIVE STUDY; TETRAPLOIDY; ADENOCARCINOMA; DISEASE COURSE; ESOPHAGUS TUMOR; GENETICS; PATHOLOGY; PREVALENCE; RISK FACTOR;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; METAPLASIA; PREVALENCE; RISK FACTORS;

EID: 67549148933     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318198a1d4     Document Type: Article

References (20)

1. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett's esophagus. Nat Gen. 1999;22:106-109.
2. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: prospective study. Am J Gastroenterol. 2003;98:1931-1939.
3. Drewitz DJ, Sampliner RE, Garewall HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92: 212-215.
4. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for future esophageal adenocarcinoma. PLoS Med. 2007;4:e67.
5. Haggitt RC, Tryzelaar J, Ellis H, et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol. 1978;90:1-5.
6. Levine DS, Reid BJ. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc. 1991;37:332-337.
7. Maley CC, Galipeau PC, Li X, et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 2004;64:3414-3427.
8. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 2004;64:7629-7633.
9. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:468-473.
10. Montgomery E, Bronner M, Goldblum J, et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
11. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379-388.
12. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol. 2006;59:1029-1038.
13. Park DY, Srivastava A, Kim GH, et al. Adenomatous and foveo-lar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol. 2008;32: 524-533.
14. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression Barrett's esophagus: III. Baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071-3083.
15. Reid BJ, Haggitt RC, Rubin CE. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988;19:166-178.
16. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669-1676.
17. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus: II. Baseline 17p(p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839-2848.
18. Riddell RH, Goldman H, Ransohoff DE, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical information. Hum Pathol. 1983;14:931-968.
19. Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol. 2009;40:65-74.
20. Wang K, Sampliner R. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastrenterol. 2008;103:788-797.